Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1999-07-06
2001-05-01
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S912000
Reexamination Certificate
active
06225303
ABSTRACT:
TECHNICAL FIELD
The invention is in the field of photodynamic therapy, specifically related to ocular conditions. More particularly, the invention concerns the use of green porphyrins in photodynamic therapeutic treatment of conditions characterized by unwanted neovasculature in the eye.
BACKGROUND ART
Choroidal neovascularization leads to hemorrhage and fibrosis, with resultant visual loss in a number of eye diseases, including macular degeneration, ocular histoplasmosis syndrome, myopia, and inflammatory diseases. Age-related macular degeneration (AMD) is the leading cause of new blindness in the elderly, and choroidal neovascularization is responsible for 80% of the severe visual loss in patients with this diseases. Although the natural history of the disease is eventual quiescence and regression of the neovascularization process, this usually occurs at the cost of sub-retinal fibrosis and vision loss.
Current treatment of AMD relies on occlusion of the blood vessels using laser photocoagulation. However, such treatment requires thermal destruction of the neovascular tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the subject is left with an atrophic scar and-visual scotoma. Moreover, recurrences are common, and visual prognosis is poor.
Developing strategies have sought more selective closure of the blood vessels to preserve the overlying neurosensory retina. One such strategy is photodynamic therapy, which relies on low intensity light exposure of photosensitized tissues to produce photochemical effects. Photosensitizing dyes are preferentially retained in tumors and neovascular tissue, which allows for selective treatment of the pathologic tissue. As a result of the invention, PDT may be used to cause vascular occlusion in tumors by damaging endothelial cells, as well as a direct cytotoxic effect on tumor cells.
Photodynamic therapy of conditions in the eye characterized by neovascularization has been attempted over the past several decades using the conventional porphyrin derivatives such as hematoporphyrin derivative and Photofrin porfimer sodium. Problems have been encountered in this context due to interference from eye pigments. In addition, phthalocyanine has been used in photodynamic treatment.
A newer photosensitizer, a member of the group designated “green porphyrins”, is in the class of compounds called benzoporphyrin derivatives (BPD). This photosensitizer has also been tested to some extent in connection with ocular conditions. For example, Schmidt, U. et al. described experiments using BPD coupled with low density lipoprotein (LDL) for the treatment of Greene melanoma (a nonpigmented tumor) implanted into rabbit eyes and achieved necrosis in this context (IOVS (1992) 33:1253 Abstract 2802). This abstract also describes the success of LDL-BPD in achieving thrombosis in a corneal neovascularization model. The corneal tissue is distinct from that of the retina and choroid.
The present applicants have described treating choroidal neovascularization using LDL-BPD in several abstracts published Mar. 15, 1993. These abstracts include those by Schmidt-Erfurth, U. et al. (abstract 2956); by Haimovici, R. et al. (abstract 2955); and by Walsh, A. W. et al. (abstract 2954). In addition, Lin, S. C. et al. described photodynamic closure of choroidal vessels using liposomal BPD in (abstract 2953). All of the foregoing are published in IOVS (1993) 34:1303. An additional abstract of the present applicants describing LDL-BPD to inhibit choroidal neovasculature is by Moulton, R. S. et al. (abstract 2294), IOVS (1993) 34:1169.
The green porphyrins offer advantages in their selectivity for neovasculature. The present applicants have further determined that coupling of the green porphyrins to a carrier such as LDL or as contained-in a liposomal formulation provides an advantageous delivery method for the drug to the desired ocular location.
DISCLOSURE OF THE INVENTION
The invention is directed to diagnosis and treatment of certain conditions of the eye using photodynamic methods and employing green porphyrins as the photoactive compounds. The green porphyrins of the invention are described in U.S. Pat. Nos. 4,883,790; 4,920,143; 5,095,030; and 5,171,749, the entire contents of which are incorporated herein by reference. These materials offer advantages of selectivity and effectiveness when employed in protocols directed to the destruction of unwanted ocular neovasculature, especially in the choroid.
Accordingly, in one aspect, the invention is directed to a method to treat conditions of the eye characterized by unwanted neovasculature, which method comprises administering to a subject in need of such treatment an amount of a liposomal formulation of green porphyrin that will localize in said neovasculature; and irradiating the neovasculature with light absorbed by the green porphyrin.
In another aspect, the invention is directed to a method to treat conditions of the choroid characterized by unwanted neovascularization, such as AMD, which method comprises administering to a subject in need of such treatment an amount of a green porphyrin that will localize in the neovascularized choroid; and irradiating the choroid with light absorbed by the green porphyrin.
In still another aspect, the invention is directed to a method to treat age-related macular degeneration (AMD) which method comprises administering to a subject in need of such treatment an amount of green porphyrin that will localize in the choroid and irradiating the choroid with light absorbed by the green porphyrin.
REFERENCES:
patent: 4883790 (1989-11-01), Levy et al.
patent: 4920143 (1990-04-01), Levy et al.
patent: 5087636 (1992-02-01), Jamieson et al.
patent: 5171749 (1992-12-01), Levy et al.
patent: 5214036 (1993-05-01), Allison et al.
patent: 5283255 (1994-02-01), Levy et al.
patent: 5705518 (1998-01-01), Richter et al.
patent: 5770619 (1998-06-01), Richter et al.
patent: 5798349 (1998-08-01), Levy et al.
Haimovici et al., “Localization of Benzoporphyrin Derivative Monoacid in the Rabbit Eye,”Investigative Opthalmology and Visual Science, (1993) 34:1303 Abstracts 2955.
Lin et al., “Measurement of BPD Photosensitizer Kinetics in Retinal and Choroidal Vessels by Fluorescence Imaging,”Investigative Opthalmology and Visual Science(1993) vol. 34, p. 1168, Abstract No. 2293.
Lin et al., “Photodynamic Closure of Choroidal Vessels Using Benzoporphyrin Derivatives,”Investigative Opthalmology and Visual Science(1993) 34:1303 Abstract 2953.
Moulton et al., “Response of Retinal and Choroidal Vessels to Photodynamic Therapy Using Benzoporphyrin Derivative Monoacid,”Investigative Opthalmology and Visual Science(1993) 34:1169 Abstract 2294.
Pandey et al., “Efficient Synthesis of New Classes of Regiochemically Pure Benzoporphyrin Derivatives,”Bioorganic&Medicinal Chemistry Letters(3) 12:2615-2618 (1993).
Schmidt-Erfuth et al., “Photothrombosis of Ocular Neovascularization Using Benzoporphyrin (BPD),”Investigative Opthalmology and Visual Science(1993) 34:1303 Abstracts 2956.
Schmidt-Erfurth et al., “Photodynamic Therapy of Experimental Melanoma Using Lipoprotein-Delivered Benzoporphyrin,”Opthalmology(1994) 101(1):89-99.
Schmidt et al., “Photosensitizing Potency of Benzoporphyrin Derivative (BPD) Associated with Human Low Density Lipoprotein (LDL),”Investigative Opthalmology and Visual Science(1992) 33:1253 Abstract 2802.
Walsh et al., “Photodynamic Therapy of Experimental Choroidal Neovascularization Using Benzoporphyrin Derivative Monoacid,”Investigative Opthalmology and Visual Science(1993) 34:1303 Abstracts 2954.
Richter et al., “Characterization of Benzoporphyrin Derivative, A New Photosensitizer,”SPIE97 (Advances in Photochemotherapy), 132-138 (1988).
Kessel, D., “Photosensitization With a Benzoporphyrin Derivative,”Photochemistry and Photobiology(1989) 49(5):579-582.
Richter et al., “In Vitro Evaluation of Phototoxic Properties of Four Structurally Related Benzoporphyrin Derivatives,”Photochemistry and Photobiology, (1990) 52(3):495-500.
Allison
Gragoudas Evangelos S.
Miller Joan W.
Fay Zohreh
Massachusetts Eye and Ear Infirmary
Testa Hurwitz & Thibeault LLP
LandOfFree
Use of green porphyrins to treat neovasculature in the eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of green porphyrins to treat neovasculature in the eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of green porphyrins to treat neovasculature in the eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2486520